Seismed Instruments Inc SEIS 深 滬
已收盤 09-19 16:00:00 美东时间
28.3411
-0.252
-0.88%
華盛通- 最 高28.61
- 今 開28.61
- 成交量 4.08万股
- 最 低 28.28
- 昨 收 28.5935
- 總市值 2.98亿
- 52周最高 28.62
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 20.2664
- 委 比 0.00%
- 總股本 1052.68万
- 歷史最高 28.62
- 量 比 1.16
- 振 幅 1.15%
- 歷史最低 20.2664
- 每 手 1
- 風險率 1.57%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多TANSEISHA Adopts New Capital and Stock Price Management Policy
An announcement from TANSEISHA Co., Ltd. ( ($JP:9743) ) is now available. TANSE...
09-12 15:11
TANSEISHA Reports Robust Growth and Increased Dividends
An update from TANSEISHA Co., Ltd. ( ($JP:9743) ) is now available. TANSEISHA C...
09-12 15:10
Windtree Therapeutics Terminates SEISMiC-C Clinical Study
Windtree Therapeutics ( ($WINT) ) has shared an announcement. Windtree Therapeu...
08-09 05:18
Windtree Therapeutics Performs Planned Interim Analysis Of SEISMiC C Phase 2 Study Data Evaluating Istaroxime In SCAI Stage C Cardiogenic Shock
Istaroxime was added to currently available inotropes and vasopressors in the study - no new safety signals were identified and physiological improvements were consistent with istaroxime responses in previous
08-05 21:04
Windtree Therapeutics Reaches Planned Enrollment Of 20 Patients For Interim Analysis In Istaroxime Phase 2 SEISMiC C Study In SCAI Stage C Cardiogenic Shock Patients
The SEISMiC C Study is the third study in the istaroxime cardiogenic shock development program - SEISMiC C is studying more severely ill SCAI Stage C cardiogenic shock patientsWindtree has previously reported two
06-30 21:02
Windtree Therapeutics' Istaroxime Achieves Success In Phase 2 SEISMiC B Study, Meeting Primary Endpoint And Showing Cardiogenic Shock Benefits Without Increasing Heart Rate Or Renal Risk
The Phase 2 Istaroxime study was successful in multiple endpoints showing promise for how it may be utilized if approved in its targeted indications Primary endpoint of the study was met of increasing
06-16 20:12
TANSEISHA Co., Ltd. Revises Earnings and Dividend Forecasts Upward
TANSEISHA Co., Ltd. ( ($JP:9743) ) just unveiled an announcement. TANSEISHA Co....
06-13 15:07
Windtree Therapeutics Plans Interim Analysis Results For Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study For July 2025
Istaroxime has previously completed two positive Phase 2 studies in SCAI Stage B cardiogenic shock; the SEISMiC C study in SCAI Stage C cardiogenic shock is another step progressing to the istaroxime cardiogenic shock
05-22 20:17
NextDecade Provides Q1 And Early Q2 2025 Business Update
Significant Recent DevelopmentsConstructionUnder the EPC contracts with Bechtel Energy Inc. (Bechtel), Phase 1 progress is tracked for Train 1, Train 2, and the common facilities on a combined basis and Train 3 on a
05-07 05:03
Windtree Therapeutics Initiates SEISMiC C Study Of Istaroxime In SCAI Stage C Cardiogenic Shock For Planned Completion Of Phase 2b And Transition To Phase 3
After successful SEISMiC A and B studies in Early Cardiogenic Shock, SEISMiC C will treat more severe SCAI Stage C cardiogenic shock to complete the assessment of the intended Phase 3 patient populationWindtree plans to
2024-10-30 20:16
